Maan Zrein

Dr. Maan Zrein

orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2002 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
HHHans-Jochen Hagedorn
Hans-Jochen Hagedorn
AKAnna Kraminer-Hagedorn
Anna Kraminer-Hagedorn
KBKatrien De Bosschere
Katrien De Bosschere
FHFrank Hulstaert
Frank Hulstaert
HPHans Pottel
Hans Pottel
MZMaan Zrein
Maan Zrein
We evaluated the sensitivity and specificity of a new confirmatory test for treponemal antibodies, INNO-LIA Syphilis (Innogenetics NV, Ghent, Belgium), on a large number of sera from a clinical laboratory. This multiparameter line immunoassay (LIA) uses recombinant and synthetic polypeptide antigens derived from Treponema pallidum proteins. In a single-blinded cross-sectional retrospective study, 289 seronegative sera, 219 seropositive sera, and 23 sera with an indeterminate serological status for syphilis were analyzed. All sera were tested by the T. pallidum hemagglutination assay (TPHA), the immunoglobulin (IgG)-fluorescent T. pallidum absorption assay (IgG-FTA-ABS), and the Venereal Disease Research Laboratory (VDRL) test. In addition, some seropositive samples were analyzed by the 19S-IgM-FTA-ABS test, an enzyme immunoassay (IgM-EIA), and the MarDx immunoblotting assay. Based on a consensus diagnosis derived from conventional serology, all of the sera were classified as positive, negative, or indeterminate, and the results were compared with the findings of the INNO-LIA Syphilis assay. The sensitivity and specificity of the LIA were 100% (219 of 219) and 99.3% (286 of 288), respectively. Compared to TPHA and IgG-FTA-ABS, the new test gave a significantly higher number ( P = 0.021 and P < 0.0001, respectively) of correct results than either of the other two tests. The multiparameter INNO-LIA Syphilis assay is a useful confirmatory test for syphilis because it increases the reliability of syphilis diagnosis with respect to current conventional techniques.

23 April 2020 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
JPJulio Alonso Padilla
Julio Alonso Padilla
MAMarcelo Abril
Marcelo Abril
BNBelkisyolé Alarcón De Noya
Belkisyolé Alarcón De Noya
IAIgor C Almeida
Igor C Almeida
AAAndrea Angheben
Andrea Angheben
APAlbert Picado
Albert Picado

1 April 2016 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
EGElodie Granjon
Elodie Granjon
MDMarie-Laure Dichtel-Danjoy
Marie-Laure Dichtel-Danjoy
ESEsber Saba
Esber Saba
ESEster Sabino
Ester Sabino
LOLea Campos de Oliveira
Lea Campos de Oliveira
MZMaan Zrein
Maan Zrein
Chagas disease is due to the parasite Trypanosoma cruzi, a protist disseminated by a Triatome vector. This disease is endemic to Latin America and considered by WHO as one of the 17 world’s neglected diseases. In Europe and in North America, imported cases are also detected, due to migration of population outside of the endemic region. Diagnosis of T. cruzi infection is usually made indirectly by the detection of specific antibodies to T. cruzi antigens. Following initial diagnostic evaluation or screening test (qualifying or discarding blood donation), a confirmation test is performed for samples initially reactive. The test presented in this study aims at the confirmation/refutation of the infectious status of human blood samples and will permit taking appropriate clinical measures. We designed a novel array of twelve antigens and printed these antigens onto 96-well plates. We tested 248 positive samples T. cruzi, 94 unscreened blood donors’ samples from non-endemic area, 49 seronegative blood donors, 7 false-positive and 3 doubtful samples. The observed reactivities were analyzed to propose a decision-tree algorithm that correctly classifies all the samples, with the potential to discriminate false-positive results and sticky samples. We observed that antibodies levels (Sum of all antigens) was significantly higher for PCR positive than for PCR negative samples in all studied groups with Multi-cruzi. The results described in this study indicate that the Multi-cruzi improves the serological confirmation of Chagas disease. Moreover the “sum of all antigens” detected by Multi-cruzi could reflect parasitemia level in patients–like PCR signals does—and could serve as an indicator of parasite clearance in longitudinal follow-ups. Validation of this assay is still required on an independent large collection of well characterized samples including typical false-reactive samples such as Leishmaniasis. Eight million people are affected by Chagas disease worldwide, almost exclusively in South America. This chronic disease is initially asymptomatic but turns out to be life threatening in 30% of the cases, years after the infection. Two therapies are available, but their efficacy is maximal if the treatment is initiated shortly after contamination. In the absence of reliable symptoms, the in vitro diagnostic of Chagas Disease is thus a crucial tool to implement accurate clinical management. In order to permit universal access and a reliable confirmation of Chagas’s parasite presence, we have developed a new multiplex platform using a large number of selected antigens on easy handling 96 well ELISA microplates. In this manuscript, we present the first optimization data of the Multi-cruzi test that shows promising results for Chagas disease confirmation.

1 February 2000 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
ASAmadeo Saez-Alquézar
Amadeo Saez-Alquézar
ESEster C. Sabino
Ester C. Sabino
NSNanci Salles
Nanci Salles
DCDalton F. Chamone
Dalton F. Chamone
FHFrank Hulstaert
Frank Hulstaert
MZMaan Zrein
Maan Zrein
Although screening for Trypanosoma cruzi antibodies is mandatory in most South American countries, current tests are insensitive and have poor specificity. A recently optimized line immunoassay (the INNO-LIA Chagas assay) for the serological confirmation of Chagas' disease was evaluated at a large blood bank in São Paulo, Brazil. Sera from blood donors who reacted in at least one of three serological screening assays ( n = 1,604) and who returned for a follow-up were retested, and the donors were interviewed to assess their epidemiological risk. The results obtained by the confirmatory assay evaluated in this study were compared to those obtained by the three different screening assays. Upon consideration of the consensus results obtained by the three different screening assays as a “gold standard,” the INNO-LIA Chagas assay showed a sensitivity of 99.4% (95% confidence interval [CI], 98.3 to 99.9) and a specificity of 98.1% (95% CI, 96.6 to 99.0) for positive ( n = 503) and negative ( n = 577) sera. The INNO-LIA Chagas assay confirmed the results for significantly larger numbers of positive samples of at-risk individuals independent of the number of positive screening tests ( P = 0.017, Mantel-Haenszel test). In conclusion, the INNO-LIA Chagas assay reliably confirmed the presence of antibodies to T. cruzi and can be implemented as a confirmatory assay for Chagas' disease serology.

1 May 1999 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
ESEster Cerdeira Sabino
Ester Cerdeira Sabino
MZMaan Zrein
Maan Zrein
CTCarlos P. Taborda
Carlos P. Taborda
MOMarcia M. Otani
Marcia M. Otani
GRGabriela Ribeiro-Dos-Santos
Gabriela Ribeiro-Dos-Santos
ASAmadeo Sáez-Alquézar
Amadeo Sáez-Alquézar
We have evaluated a new serological confirmatory test (INNO-LIA HTLV I/II Ab [INNO-LIA]) for human T-cell leukemia virus (HTLV) using a large collection of samples from Brazilian blood donors (São Paulo region) and compared the results with those obtained by Western blotting (WB) tests (WB2.3 and WB2.4). Blood donations were initially screened by enzyme-linked immunosorbent assays (ELISAs) based on viral lysates, and repeatedly reactive samples were further tested by WB2.3. When available, samples were also tested by PCR, two additional ELISAs based on recombinant antigens (recombinant ELISAs), a new-generation WB assay (WB2.4), and the INNO-LIA. Of the 18,169 samples tested, 292 (1.61%) were repeatedly reactive in the ELISAs (viral lysate based) and were further tested by WB2.3; 97 were positive (19 that were typed as HTLV type I [HTLV-I], 12 that were typed as HTLV type II [HTLV-II], and 66 that were nontypeable), 17 were negative, and 178 had indeterminate results. Of the samples with indeterminate results, 172 were tested by INNO-LIA, which could resolve 153 samples as negative. Regarding the positive samples, WB2.3 and INNO-LIA produced concordant results for all HTLV-I-positive samples, whereas for HTLV-II they agreed for 10 of 12 samples; the 2 samples with discordant results were considered to be positive for HTLV-II by WB with WB2.3 but negative for HTLV-II by INNO-LIA and the two recombinant ELISAs. Furthermore, of the 66 nontypeable samples, 60 underwent testing by INNO-LIA; 54 turned out to be negative by the latter test as well as by recombinant ELISAs. In conclusion, the new serological confirmatory assay for HTLV (INNO-LIA HTLV I/II Ab) resolved the results for the majority of the indeterminate and positive-untypeable samples frequently observed by WB assays.

1 January 2000 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
AEAnne Ebel
Anne Ebel
LVLies Vanneste
Lies Vanneste
MCMartine Cardinaels
Martine Cardinaels
ESErwin Sablon
Erwin Sablon
ISIsabelle Samson
Isabelle Samson
MZMaan Zrein
Maan Zrein
The commercially available diagnostic tests for syphilis are mostly based on the use of extracted antigens ofTreponema pallidum. Pronounced cross-reactivities with other spirochete antigens are often reported. The aim of this study was to validate a novel multiparametric assay (the assay performed with the kit) INNO-LIA Syphilis for the confirmation of syphilis antibodies in a set of 840 documented human serum samples. All serum samples were previously tested at the French World Health Organization reference center for venereal diseases (Institute Alfred Fournier, Paris, France), with a consensus result provided for each sample. The study was conducted in two phases, with each phase involving a validation set (500 well-documented serum samples) and an exploratory set (340 serum samples) of serum samples, respectively. By measuring the sensitivity and specificity, we compared the result of the new assay with the consensus result on the basis of the results of a variable number of classical serological methods and clinical information when available. A sensitivity of 99.6% (95% confidence internal [CI], 98.5 to 99.9%) and a specificity of 99.5% (95% CI, 98.1 to 99.9%) were found for the new line immunoassay. Six of seven samples with indeterminate results by classical serology tested positive with the INNO-LIA Syphilis kit. This single multiparametric assay provides reliable confirmatory diagnostic information that must currently be obtained by the performance and interpretation of results of a combination of serological assays.